EDTK - RRD ATNX and NXTP among premarket gainers
R. R. Donnelley & Sons (NYSE:RRD) +31%. Inhibrx (NASDAQ:INBX) +17% on favorable safety profile in patients with alpha-1 antitrypsin deficiency and demonstrates the potential to achieve normal alpha-1 antitrypsin levels with monthly dosing. Protara Therapeutics (NASDAQ:TARA) +26% on FDA greenlight for early-stage TARA-002 bladder cancer trial. PetVivo Holdings (NASDAQ:PETV) +15%. Draganfly (NASDAQ:DPRO) +14% on signing $9M agreement with Digital Dream Labs. Ocugen (NASDAQ:OCGN) +13% on partnering COVID-19 vaccine gets emergency use nod for kids in India. Quanterix (NASDAQ:QTRX) +13% after FDA Breakthrough Device status for pTau-181 blood test. Westwater Resources (NYSE:WWR) +11% to push ahead with planned Alabama battery graphite plant. Poseida Therapeutics (NASDAQ:PSTX) +11% on research collaboration with Takeda for gene therapies. Nutriband (OTCQB:NTRB) +10% on exclusive manufacturing pact for Diocheck technology. Standard Lithium (NYSE:SLI) +10% on preliminary assessment of Arkansas project. Tiptree (NASDAQ:TIPT) +9% on announcing $200M strategic investment in Fortegra. Alzamend Neuro (NASDAQ:ALZN) +8%. Athenex (NASDAQ:ATNX) +8%. Summit Wireless Technologies (NASDAQ:WISA) +8% reports Q3 revenue growth of 200% to
For further details see:
RRD, ATNX and NXTP among premarket gainers